Drug-Linker Conjugates for ADC
Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.
The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.
ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.
Drug-Linker Conjugates for ADC Isoform Specific Products
-
Drug-Linker Conjugates for ADC
(327)
View all products
-
Auristatin
(45)
View all products
-
Camptothecins
(33)
View all products
-
Daunorubicins/
Doxorubicins (5)View all products
-
Duocarmycins
(8)
View all products
-
Maytansinoids
(19)
View all products
-
Pyrrolobenzodiazepines
(5)
View all products
-
Traditional Cytotoxic Agents
(31)
View all products
-
Dual payloads
(5)
View all products
All Product Categories
-
Drug-Linker Conjugates for ADC Related Products (500)
Related Products (500)
-
Drug-Linker Conjugates for ADC Isoform Comparison
-
PC6-VC-PAB-MMAE
0 ImagesCat. No.: HY-157501CAS No.: 2922217-01-2PC6-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. PC6-VC-PAB-MMAE consists of the ADC Cytotoxin MMAE (HY-15162) and a linker. PC6-VC-PAB-MMAE can be used for synthesis of ADCs.
-
SG3376
0 ImagesCat. No.: HY-160087CAS No.: 2139261-06-4SG3376 is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). SG3376 is promising for research of HER2-overexpressing cancers (e.g., breast, gastric cancer).
-
MC7
0 ImagesCat. No.: HY-164707CAS No.: 2222981-66-8MC7 is a drug-linker conjugate that can be used in research related to ADC synthesis. The payload of MC7 is a NAMPT inhibitor (HY-402237).
-
NHS-Modified MMAF
0 ImagesCat. No.: HY-139325CAS No.: 1404073-10-4NHS-Modified MMAF (WO2012143499A2, intermediat 210) is an intermediate which can be used for producing the anti-mesothelin binder-agent conjugates (ADCs).
-
LM-D01
0 ImagesCat. No.: HY-178260CAS No.: 3035271-58-7LM-D01 is a Drug-Linker Conjugates for ADC. LM-D01 consists of the ADC Cytotoxin Exatecan-3-amine (HY-178265) and a linker MC-GGFG-NH-CH2-O-propionic acid (HY-178266). LM-D01 can be used for synthesis of ADCs.
-
2',3'-cGAMP-C2-PPA
0 ImagesCat. No.: HY-141662CAS No.: 2586047-11-02’,3’-cGAMP-C2-PPA is a cyclic dinucleotide interferon gene-stimulating protein (STING) agonist. 2’,3’-cGAMP-C2-PPA is a drug conjugated conjugate used to target antibody-drug conjugated conjugate (ADC) for the treatment of cancer. 2’,3’-cGAMP-C2-PPA can be used in the study of immune and tumor-related diseases.
-
2-MSP-VA-PAB-MMAE
0 Images2-MSP-VA-PAB-MMAE (Compound B-2) is a conjugate of the toxin molecule MMAE (HY-15162) and a linker, which can be used to construct antibody-drug conjugates (ADCs).
-
MC-betaglucuronide-MMAE-2
0 ImagesCat. No.: HY-136321CAS No.: 1703778-81-7MC-betaglucuronide-MMAE-2 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.
-
Mal-PEG8-Val-Ala-Exatecan
0 ImagesMal-PEG8-Val-Ala-Exatecan (Compound 1033) is a Drug-Linker Conjugates for ADC, which is composed of Exatecan (HY-13631) and a linker. Mal-PEG8-Val-Ala-Exatecan can be used for ADC synthesis.
-
Mal-amido-PEG8-Val-Ala-PAB-SG3200
0 ImagesCat. No.: HY-139957CAS No.: 2025353-40-4Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a conjugate for antibody-drug conjugate (ADC) (extracted from patent WO2016166300A1).
-
7-O-(Cbz-N-amido-PEG4)-paclitaxel
0 ImagesCat. No.: HY-1411487-O-(Cbz-N-amido-PEG4)-paclitaxel is a PEG-class Drug-linker conjugates for ADC, containing a paclitaxel moiety and a amino group. The amine group is reactive with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. 7-O-(Cbz-N-amido-PEG4)-paclitaxel can be used in the synthesis of Antibody-Drug Conjugates (ADCs).
-
LE01
0 ImagesCat. No.: HY-168285CAS No.: 2718125-83-6LE01 is a drug-linker conjugate for ADC. LE01 contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D). LE01 can be used to synthesize HER2-targeting ADC (HER2-LE01).
-
diSPhMC-Asn-Pro-Val-PABC-MMAE
0 ImagesCat. No.: HY-144630CAS No.: 2893871-68-4diSPhMC-Asn-Pro-Val-PABC-MMAE (compound 9) is a potent ADC Linker used in the synthesis of antibody-drug conjugates (ADCs).
-
Mal-C5-Gly-Gly-Phe-MMAE
0 ImagesCat. No.: HY-164829CAS No.: 3056230-14-6
-
N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan)
0 ImagesCat. No.: HY-177686N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
-
SMP-33693
0 ImagesCat. No.: HY-153909SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer.
-
Mal-VC-PAB-PNP-CDN-A
0 ImagesCat. No.: HY-148399CAS No.: 2640880-35-7Mal-VC-PAB-PNP-CDN-A is a drug-Linker conjugates for ADC.
-
Fmoc-Val-Cit-PAB-Exatecan
0 ImagesCat. No.: HY-177548CAS No.: 2754384-69-3Fmoc-Val-Cit-PAB-Exatecan is a Drug-linker conjugate for ADC. Fmoc-Val-Cit-PAB-Exatecan contains the ADC linker (Fmoc-Val-Cit-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631).
